Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.47 |
| ▸ | RXRA | P19793 | 10/20 | 0.42 |
| ▸ | RXRB | P28702 | 10/20 | 0.42 |
| ▸ | RXRG | P48443 | 8/20 | 0.42 |
| ▸ | RARB | P10826 | 7/20 | 0.42 |
| ▸ | RARG | P13631 | 7/20 | 0.42 |
| ▸ | RARA | P10276 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743105 | 0.81 | CYP26B1 (0.50) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL15209657 | 0.81 | KDM1A (0.37) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL12878863 | 0.78 | CA12 (0.40) | CYP26B1RXRARXRBRXRGCYP3A4 | |
| SCHEMBL6472698 | 0.77 | CYP26B1 (0.47) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL6473308 | 0.77 | CYP26B1 (0.47) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL15805655 | 0.77 | RARB (0.47) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL17049099 | 0.73 | RXRA (0.68) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL7723491 | 0.73 | RXRA (0.69) | CYP26B1CYP26A1RXRARXRBRXRG | |
| SCHEMBL5656647 | 0.73 | NOTUM (0.44) | CYP26B1CYP26A1RXRARARBRARG | |
| SCHEMBL24259942 | 0.72 | CYP26B1 (0.57) | CYP26B1CYP26A1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-21 | — | — | US | disclosed |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2021-07-22 | — | — | US | disclosed |
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-12-29 | — | — | US | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| CN-101378757-B | Thiadiazole derivatives for the treatment of neuro degenerative diseases | REMYND NV | 2012-08-01 | — | — | CN | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| EP-0638071-A1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR). | EISAI CO LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994014777-A1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR) | EISAI CO., LTD. (JP) | 1994-07-07 | — | — | WO | disclosed |
| US-5248823-A | Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-28 | — | — | US | disclosed |
| EP-0386452-B1 | DIPHENYL HETEROALKYL DERIVATIVES, THEIR PREPARATION AND MEDICINAL AND COSMETIC PREPARATIONS PREPARED THEREFROM | BASF Aktiengesellschaft (DE) | 1993-09-22 | — | — | EP | disclosed |
| US-5225601-A | Sulfur containing compounds for skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| EP-0386451-B1 | OXYGEN-BEARING DIPHENYL HETEROALKANES, PROCESS FOR THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1993-04-28 | — | — | EP | disclosed |
| US-5128479-A | Skin disorders, cosmetics | BASF AKTIENGESELLSCHAFT (DE) | 1992-07-07 | — | — | US | disclosed |
| US-5087743-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-11 | — | — | US | disclosed |
| EP-0386451-A1 | Oxygen-bearing diphenyl heteroalkanes, process for their preparation and use | BASF Aktiengesellschaft (DE) | 1990-09-12 | — | — | EP | disclosed |
| EP-0386452-A1 | Diphenyl heteroalkyl derivatives, their preparation and medicinal and cosmetic preparations prepared therefrom | BASF Aktiengesellschaft (DE) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | CYP26B1, CYP2A6, CYP26A1 | CYP26B1 1/4885CYP26A1 3/4885RXRA 12/4885 |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | CYP2A6, CYP27A1, CYP26B1 | CYP26B1 3/4885CYP26A1 4/4885RXRA 37/4885 |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | CYP2A6, CYP27A1, CYP26B1 | CYP26B1 3/4885CYP26A1 4/4885RXRA 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.